Strokes within pediatric populations are considered to be the 10th leading cause of death in the United States of America, with over half of such events occurring in children younger than one year of life. The multifactorial etiopathology that has an influence on stroke development and occurrence signify the importance of the timely recognition of both modifiable and non-modifiable factors for adequate diagnostic and treatment approaches. The early recognition of a stroke and stroke risk in children has the potential to advance the application of neuroprotective, thrombolytic, and antithrombotic interventions and rehabilitation strategies to the earliest possible timepoints after the onset of a stroke, improving the outcomes and quality of life for affected children and their families. The recent development of molecular genetic methods has greatly facilitated the analysis and diagnosis of single-gene disorders. In this review, the most significant single gene disorders associated with pediatric stroke are presented, along with specific therapeutic options whenever they exist. Besides monogenic disorders that may present with stroke as a first symptom, genetic polymorphisms may contribute to the risk of pediatric and perinatal stroke. The most frequently studied genetic risk factors are several common polymorphisms in genes associated with thrombophilia; these genes code for proteins that are part of the coagulation cascade, fibrolysis, homocystein metabolism, lipid metabolism, or platelets. Single polymorphism frequencies may not be sufficient to completely explain the stroke causality and an analysis of several genotype combinations is a more promising approach. The recent steps forward in our understanding of the disorders underlying strokes has given us a next generation of therapeutics and therapeutic targets by which to improve stroke survival, protect or rebuild neuronal connections in the brain, and enhance neural function. Advances in DNA sequencing and the development of new tools to correct human gene mutations have brought genetic analysis and gene therapy into the focus of investigations for new therapeutic options for stroke patients.

During the last three years, since the emergence of the COVID-19 pandemic, a significant number of scientific publications have focused on resolving susceptibility to the infection, as well as the course of the disease and potential long-term complications. COVID-19 is widely considered as a multisystem disease and a variety of socioeconomic, medical, and genetic/epigenetic factors may contribute to the disease severity and outcome. Furthermore, the SARS-COV-2 infection may trigger pathological processes and accelerate underlying conditions to clinical entities. The development of specific and sensitive biomarkers that are easy to obtain will allow for patient stratification, prevention, prognosis, and more individualized treatments for COVID-19. miRNAs are proposed as promising biomarkers for different aspects of COVID-19 disease (susceptibility, severity, complication course, outcome, and therapeutic possibilities). This review summarizes the most relevant findings concerning miRNA involvement in COVID-19 pathology. Additionally, the role of miRNAs in wide range of complications due to accompanied and/or underlying health conditions is discussed. The importance of understanding the functional relationships between different conditions, such as pregnancy, obesity, or neurological diseases, with COVID-19 is also highlighted.

The identification of mild fetal ventriculomegaly prompts further evaluation focused on determining whether additional structural anomalies, genetic abnormalities or congenital infections are present. The aim of this study is to evaluate the frequency of chromosomal aberrations in fetuses with isolated mild symmetrical ventriculomegaly and determine the risk for a fetus with isolated mild ventriculomegaly to have chromosomal abnormality in a back ground. Additionally, we have performed an evaluation of the chromosomal microarray findings in a series of five fetuses with isolated mild symmetrical ventriculomegaly and a normal karyotype. The retrospective observational study included karyotype evaluation of 102 fetuses with isolated mild symmetrical ventriculomegaly identified at the time of the routine midpregnancy scanning. In five cases array-CGH was performed and the obtained data were compared with the data in the bioinformatics databases. Among fetuses with isolated mild symmetrical ventriculomegaly chromosome aberrations were found in 2 (1,96%) fetuses. In both cases autosomal aneuploidy was detected, and those are trisomy 21 and trisomy 18, respectively. The finding of a mild symmetrical isolated ventriculomegaly on the routine ultrasound fetal exam in the second trimester had low sensitivity, but high specificity and negative predictive value in the prediction of chromosome anomalies. Copy number variants (microduplications/microdeletions) were detected in four cases (80%). A search for the similar variants in NCBI ClinVar, DECIPHER, OMIM and ENSEMBL data bases, revealed that the microdeletions/microduplications detected in four fetuses in our study cannot be related with ventriculomegaly development. Our findings suggest that karyotyping is not justified in fetuses with isolated mild symmetrical ventriculomegaly (10-15 mm), in a low risk population. Therefore, when mild fetal ventriculomegaly is found in a low risk population, additional non-invasive procedures for chromosome aberration screening (such as noninvasive prenatal screening based on cell-free fetal DNA) are recommended, before making the decision to perform invasive diagnostic procedures.

This study evaluates how chromosomal factors affect assisted reproduction techniques (ART) challenges among infertile couples, impacting their chances of conception. Chromosomal abnormalities, a leading cause of pregnancy failure and miscarriages, were investigated in a four-year retrospective study involving 100 patients with a history of infertility and unsuccessful IVF treatment. Among these cases, nine (9%) displayed aberrant chromosomal patterns, including balanced translocations (5%), sex chromosome deletions (3%), and one case of a small supernumerary marker chromosome (sSMC) (1%). The results of the present study highlight the importance of integrating comprehensive cytogenetic analysis as a routine diagnostic tool for individuals dealing with infertility, particularly before assisted reproduction techniques, to avert recurrent implantation failure and to enhance their chances of success.

Congenital anomalies of the reproductive system represent a heterogeneous group of structural and functional abnormalities affecting both male and female genital organs. These anomalies typically arise during embryogenesis and may remain asymptomatic until they are incidentally identified during evaluation for infertility, recurrent pregnancy loss, or disorders of sexual development. In females, abnormalities include Müllerian duct anomalies and congenital malformations of the uterus, cervix, vagina, and ovaries, such as Mayer–Rokitansky–Küster–Hauser syndrome, septate, unicornuate, bicornuate, and didelphys uteri, and ovarian agenesis and undescended ovaries. In males, congenital conditions such as anorchia, cryptorchidism, hypospadias, ejaculatory duct obstruction, and ejaculatory dysfunction may be associated with impaired spermatogenesis and reduced fertility. Early recognition of these conditions may facilitate timely clinical evaluation and individualized management, which can include surgical correction, hormonal therapy, and reproductive counseling. When appropriate, early diagnosis may support multidisciplinary care, with the aim of optimizing sexual development, preserving reproductive potential, and reducing long-term morbidity associated with congenital anomalies. However, the clinical impact of early detection varies depending on the type and severity of the anomaly. A systematic and multidisciplinary approach may contribute to improved reproductive outcomes and better overall reproductive health in affected individuals. Further research is needed to better define the optimal timing and clinical utility of systematic evaluation strategies in this patient population.

Background and Objectives: Infertility is a global problem. The interaction between depression and infertility seems bidirectional, and depression may negatively influence IVF outcomes. The Beck Depression Inventory (BDI) is one of the most extensively used instruments for diagnosing depression. The aim of this study was to assess the dynamics of depression in patients undergoing IVF utilizing the BDI. Materials and Methods: This prospective cohort study was conducted at the Clinic for Gynecology and Obstetrics of the University Clinical Center of Serbia in Belgrade, Serbia during the year 2019. Both partners in the IVF program were required to complete the paper-based BDI 5 to 10 days before starting ovarian stimulation, within the 48 h preceding oocyte aspiration and four weeks after embryo transfer. We sought to identify potential predictors of a favorable IVF outcome by using logistic regression modeling. Results: Our study enrolled 86 couples. The overall IVF efficacy in our cohort was 18.6%. A statistically significant logistic regression model (p = 0.001) managed to explain 47.6% of the variability. Increasing patient age, the presence of depression (BDI > 16) and the number of failed IVF cycles were found to be significant negative predictors of ongoing IVF success. Conclusions: Depression is more common in patients undergoing IVF than in the general population. Depression might increase the odds of IVF failure, lending credence to the idea that depression screening using BDI should be a routine part of the IVF process.